1. Home
  2. DCTH vs TBPH Comparison

DCTH vs TBPH Comparison

Compare DCTH & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
    SELLHOLDBUYas of 17 hours ago
  • TBPH
    SELLHOLDBUYas of 17 hours ago
  • Stock Information
  • Founded
  • DCTH 1988
  • TBPH 2013
  • Country
  • DCTH United States
  • TBPH United States
  • Employees
  • DCTH N/A
  • TBPH N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • DCTH Health Care
  • TBPH Health Care
  • Exchange
  • DCTH Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • DCTH 518.0M
  • TBPH 464.5M
  • IPO Year
  • DCTH N/A
  • TBPH N/A
  • Fundamental
  • Price
  • DCTH $11.01
  • TBPH $8.44
  • Analyst Decision
  • DCTH Strong Buy
  • TBPH Buy
  • Analyst Count
  • DCTH 4
  • TBPH 4
  • Target Price
  • DCTH $22.75
  • TBPH $13.75
  • AVG Volume (30 Days)
  • DCTH 491.4K
  • TBPH 189.7K
  • Earning Date
  • DCTH 05-13-2025
  • TBPH 05-12-2025
  • Dividend Yield
  • DCTH N/A
  • TBPH N/A
  • EPS Growth
  • DCTH N/A
  • TBPH N/A
  • EPS
  • DCTH N/A
  • TBPH N/A
  • Revenue
  • DCTH $37,205,000.00
  • TBPH $64,381,000.00
  • Revenue This Year
  • DCTH $128.78
  • TBPH $51.09
  • Revenue Next Year
  • DCTH $54.07
  • TBPH N/A
  • P/E Ratio
  • DCTH N/A
  • TBPH N/A
  • Revenue Growth
  • DCTH 1701.69
  • TBPH 12.12
  • 52 Week Low
  • DCTH $4.26
  • TBPH $7.44
  • 52 Week High
  • DCTH $16.97
  • TBPH $10.90
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 31.21
  • TBPH 30.53
  • Support Level
  • DCTH $12.18
  • TBPH $8.72
  • Resistance Level
  • DCTH $13.39
  • TBPH $9.20
  • Average True Range (ATR)
  • DCTH 0.85
  • TBPH 0.27
  • MACD
  • DCTH -0.16
  • TBPH -0.08
  • Stochastic Oscillator
  • DCTH 10.34
  • TBPH 9.02

Stock Price Comparison Chart: DCTH vs TBPH

DCTH
TBPH
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April0246810121416182022DCTH VS TBPH

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use